American Head & Neck Society

Advancing Education, Research, and Quality of Care for the Head and Neck oncology patient.

Donate
Your AHNS Member Panel

Nicole Schmitt – Atlanta Georgia

Published on by

← Go back

Nicole Schmitt

Winship Cancer Institute at Emory University

  • 25
  • 18

550 Peachtree Street Northeast
11th Floor Otolaryngology
Atlanta, Georgia 30308
United States
Map It

Nicole C. Schmitt, MD, FACS, is an Acting Associate Professor in the Department of Otolaryngology and Co-Director for Translational Research in the Head and Neck Program at Winship Cancer Institute and Emory University School of Medicine. A board certified otolaryngologist, Dr. Schmitt's clinical and research work is focused on head and neck surgical oncology and novel therapeutic combinations. Dr. Schmitt is a Fellow of the American College of Surgeons, American Academy of Otolaryngology Head and Neck Surgery, and American Head and Neck Society.

 

Dr. Schmitt obtained her Medical Degree from Washington University School of Medicine in St. Louis, Missouri. She completed her general surgery internship, a research fellowship and her residency in otolaryngology at University of Washington in Seattle, Washington. She also completed a fellowship in head and neck surgery and tumor biology at University of Pittsburgh in Pittsburgh, Pennsylvania. Dr. Schmitt was on faculty at Johns Hopkins University and the National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, before joining the faculty at Emory University in 2020.

 

Dr. Schmitt's research interest is in characterizing immune effects of cytotoxic chemotherapy and designing optimal combinations of chemotherapy and immunotherapy for head and neck cancer.

ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Van Waes C, Schmitt NC. Oncoimmunology. 2020 Jan 9;9(1):1710398.

Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, Van Waes C, Schmitt NC. Oral Oncol. 2019 Aug;95:127-135.

Cisplatin alters anti-tumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC. Cancer Immunol Res 2017;5: 1141-1151.

PD-1 inhibition minimally impacts cisplatin-induced toxicities in a murine model. Spielbauer K, Cunningham L, Schmitt N. Otolaryngol Head and Neck Surg 2018; 159:343-346.

Antagonist of cIAP1/2 and XIAP synergizes with radiation therapy and PD-1 blockade to enhance anti-tumor immunity. Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC. Oncoimmunology 2018; 7:e1471440.